ATE265231T1 - Kombination von carbidopa und levodopa mit verzögerter wirkstoffabgabe - Google Patents

Kombination von carbidopa und levodopa mit verzögerter wirkstoffabgabe

Info

Publication number
ATE265231T1
ATE265231T1 AT02291229T AT02291229T ATE265231T1 AT E265231 T1 ATE265231 T1 AT E265231T1 AT 02291229 T AT02291229 T AT 02291229T AT 02291229 T AT02291229 T AT 02291229T AT E265231 T1 ATE265231 T1 AT E265231T1
Authority
AT
Austria
Prior art keywords
carbidopa
levodopa
combination
delayed release
composition
Prior art date
Application number
AT02291229T
Other languages
English (en)
Inventor
Pawan Seth
Original Assignee
Pharma Pass France S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pass France S A S filed Critical Pharma Pass France S A S
Application granted granted Critical
Publication of ATE265231T1 publication Critical patent/ATE265231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT02291229T 2001-05-29 2002-05-17 Kombination von carbidopa und levodopa mit verzögerter wirkstoffabgabe ATE265231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/866,857 US6531153B2 (en) 2001-05-29 2001-05-29 Composition with sustained release of levodopa and carbidopa

Publications (1)

Publication Number Publication Date
ATE265231T1 true ATE265231T1 (de) 2004-05-15

Family

ID=25348578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02291229T ATE265231T1 (de) 2001-05-29 2002-05-17 Kombination von carbidopa und levodopa mit verzögerter wirkstoffabgabe

Country Status (8)

Country Link
US (1) US6531153B2 (de)
EP (1) EP1262198B1 (de)
AT (1) ATE265231T1 (de)
DE (1) DE60200416T2 (de)
DK (1) DK1262198T3 (de)
ES (1) ES2222436T3 (de)
PT (1) PT1262198E (de)
TR (1) TR200401848T4 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20060159751A1 (en) * 2002-04-11 2006-07-20 Mona Gogia Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2004022745A2 (en) * 2002-09-03 2004-03-18 Universite Libre De Bruxelles Reversible, parallel and multitask cloning method and kit
ATE339192T1 (de) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
MX2007011976A (es) * 2005-03-28 2007-12-07 Orexo Ab Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson.
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP2128308B1 (de) * 2007-01-10 2012-03-14 Crystal Systems Corporation Vorrichtung zum tiegelfreien zonenschmelzen
US20090155369A1 (en) * 2007-12-13 2009-06-18 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
AU2014202306B2 (en) * 2007-12-28 2016-09-08 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
CN102202656A (zh) * 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
EP3824881B1 (de) 2018-06-18 2022-02-16 Amneal Complex Products Research LLC Pyridostigminhaltige zusammensetzungen mit verlängerter freisetzung
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua

Also Published As

Publication number Publication date
ES2222436T3 (es) 2005-02-01
US6531153B2 (en) 2003-03-11
PT1262198E (pt) 2004-09-30
DE60200416T2 (de) 2005-03-03
EP1262198B1 (de) 2004-04-28
EP1262198A1 (de) 2002-12-04
DK1262198T3 (da) 2004-08-16
TR200401848T4 (tr) 2004-09-21
US20020192290A1 (en) 2002-12-19
DE60200416D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE265231T1 (de) Kombination von carbidopa und levodopa mit verzögerter wirkstoffabgabe
IL160641A (en) Method of delivering an agrochemical benefit agent to a site in or on a plant
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE59307753D1 (de) Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
ES2076358T3 (es) Granulados con elevado contenido de ibuprofeno.
ATE344022T1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
JP2005537234A5 (de)
MY131424A (en) Amino acids with affinity for the a28 -protein
BR0208052A (pt) Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas
ES2127302T3 (es) Composiciones farmaceuticas que incluyen polimeros en silicato.
EA200400072A1 (ru) Твердая композиция, содержащая споры непатогенных бактерий рода bacillus
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
TW200603746A (en) Iron sulfate based phosphate adsorbent
MX9300336A (es) Procedimiento para la reduccion del contenido de formaldehido en formulaciones de microcapsula.
ES2063421T3 (es) Componente efervescente y procedimiento para su fabricacion.
ATE354629T1 (de) Waschmittel
WO2005030700A3 (en) Amino acids with affinity for the alpha2delta-protein
BR0008739A (pt) Composições de liberação controlada debeta-histina
PT1171111E (pt) Granulado com teor elevado de l-carnitina ou de uma alcanoil l-carnitina particularmente adequado para a producao de comprimidos por compressao directa
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
HRP20041095B1 (hr) Upotreba koncentriranog mlijeka kobile suĺ enog na biološki inertnom, visoko dispergiranom matriksu
RU2002103078A (ru) Способ профилактики диарейных болезней новорожденных телят и поросят
IL153182A0 (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1262198

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner